Literature DB >> 7093887

A prognostic factor analysis for use in development of predictive models for response in adult acute leukemia.

M J Keating, T L Smith, E A Gehan, K B McCredie, G P Bodey, E J Freireich.   

Abstract

The pretreatment characteristics of 325 adults with acute leukemia who were treated at the M. D. Anderson Hospital between 1973 and 1977 have been evaluated to assess their value as prognostic indicators. The patient population includes all patients treated with an anthracycline (Adriamycin or rubidazone), cytosine arabinoside, vincristine, and prednisone during the time period. Most patients had one of the variants of acute myelogenous leukemia (75%), and the remaining patients had acute lymphoblastic leukemia (16%) or undifferentiated leukemia (8%). Twenty-one factors were found to be significantly associated with probability of obtaining a complete response. In addition to characteristics previously known to provide prognostic information such as age, temperature status at the start of treatment, morphology, the presence of Auer rods, sex, and hemoglobin level, we identified the presence of a documented antecedent hematologic disorder and the finding of insufficient metaphases on cytogenetic analysis using the squash technique as being major prognostic variables. In addition, the pretreatment biochemical characteristics of hypoalbuminemia and elevated blood urea nitrogen and creatinine were found to adversely influence prognosis. The prognostic significance of factors such as the leukocyte count and platelet count, identified in earlier studies, was not confirmed in this group of patients. From this natural-history analysis predictive models for response have been developed using multivariate logistic regression techniques. One of these models has been used to evaluate the effect of morphology, treatment, and cytogenetic pattern on response to the combination of drugs used.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7093887     DOI: 10.1002/1097-0142(19820801)50:3<457::aid-cncr2820500313>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  High-dose cytosine arabinoside intensification for acute nonlymphocytic leukemia in patients over 56 years of age.

Authors:  A Ferrant; C Doyen; A Delannoy; L Van den Bossche; P Martiat; V Deneys; M De Bruyère; A Bosly; J L Michaux; G Sokal
Journal:  Ann Hematol       Date:  1992-04       Impact factor: 3.673

2.  Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications.

Authors:  H M Kantarjian; B Barlogie; M J Keating; R R Hall; T L Smith; K B McCredie; E J Freireich
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

3.  Treatment-subgroup interaction: an example from a published, phase II clinical trial.

Authors:  Carolyn E Behrendt; Edmund A Gehan
Journal:  Contemp Clin Trials       Date:  2009-02-21       Impact factor: 2.226

Review 4.  Acute myeloid leukemia in the elderly: biological features and search for adequate treatment.

Authors:  V Heinemann; U Jehn
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673

5.  Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients.

Authors:  P K MacCallum; A Z Rohatiner; C L Davis; J S Whelan; A M Oza; J Lim; S Love; J A Amess; M Leahy; R K Gupta
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

6.  Investigation of Biomarkers Associated with Low Platelet Counts in Normal Karyotype Acute Myeloid Leukemia.

Authors:  Chang-Hun Park; Jae Won Yun
Journal:  Int J Mol Sci       Date:  2022-07-14       Impact factor: 6.208

7.  Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California.

Authors:  Gwendolyn Ho; Ted Wun; Lori Muffly; Qian Li; Ann Brunson; Aaron S Rosenberg; Brian A Jonas; Theresa H M Keegan
Journal:  Cancer       Date:  2018-02-16       Impact factor: 6.921

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.